Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3-mediated N6-methyladenosine modification of ICAM2 mRNA in fibroblast-like synoviocytes.
Jian ChenXian LinJuan HeDandan LiuLianhua HeMiaomiao ZhangHuijie LuanYiping HuCheng TaoQingwen WangPublished in: Clinical and translational medicine (2022)
We provided strong evidence that ATT has therapeutic potential for RA management by suppressing proliferation, migration and invasion, in addition to inducing apoptosis of RA-FLSs through modulating METTL3/ICAM2/PI3K/AKT/p300 feedback loop, supplying the fundamental basis for the clinical application of ATT in RA therapy. Moreover, METTL3, ICAM2 and p300 might serve as biomarkers for the therapy response of RA patients.
Keyphrases
- rheumatoid arthritis
- signaling pathway
- pi k akt
- disease activity
- cell cycle arrest
- ankylosing spondylitis
- end stage renal disease
- interstitial lung disease
- newly diagnosed
- systemic lupus erythematosus
- ejection fraction
- cell proliferation
- chronic kidney disease
- oxidative stress
- cell death
- peritoneal dialysis
- endoplasmic reticulum stress
- stem cells
- systemic sclerosis
- mesenchymal stem cells
- binding protein
- patient reported
- cell therapy